0001650664-26-000017
SEC filingEditas Medicine, Inc. reported a net loss of $160.1 million for fiscal year 2025, driven by an operating loss of $160.0 million. Total revenue from collaboration and other research and development activities was $40.5 million. Operating expenses totaled $200.5 million, consisting of $90.0 million in research and development, $49.9 million in general and administrative expenses, and $60.7 million in restructuring and impairment charges. The company ended the year with $186.5 million in total assets, including $146.6 million in cash and cash equivalents, and $27.3 million in total stockholders' equity. Net cash used in operating activities was $165.2 million, while net cash provided by investing and financing activities was $138.7 million and $40.5 million, respectively. The company's financial position reflects ongoing investment in research and development while managing liquidity through financing activities.
Editas Medicine, Inc. reported financial results for fiscal year 2025 ending December 31, 2025. The company generated $40.5 million in collaboration and other research and development revenues. Total operating expenses were $200.5 million, comprising $90.0 million in research and development, $49.9 million in general and administrative expenses, and $60.7 million in restructuring and impairment charges. This resulted in an operating loss of $160.0 million. After accounting for other income and expenses, including $8.3 million in interest income and $6.2 million in interest expense related to sale of future revenues, the company reported a net loss of $160.1 million. Basic and diluted net loss per share was $2.00, based on 88.7 million weighted-average common shares outstanding.
The company's revenue of $40.5 million for fiscal year 2025 was derived entirely from collaboration and other research and development activities. No segment breakdown or geographic revenue mix was provided in the available data. The revenue figure represents the total recognized from collaborative arrangements and research partnerships during the period. No comparative prior period revenue figures were provided in the data, preventing year-over-year growth analysis.
Editas Medicine reported negative operating and net income margins for fiscal year 2025 due to operating expenses significantly exceeding revenue. Research and development expenses of $90.0 million represented the largest component of operating costs, followed by restructuring and impairment charges of $60.7 million and general and administrative expenses of $49.9 million. The company's cost structure reflects its focus on research and development activities in the gene editing space, with substantial investment in scientific programs and platform development.
The company used $165.2 million in cash from operating activities during fiscal year 2025, primarily driven by the net loss of $160.1 million. Investing activities provided $138.7 million in cash, mainly from $139.0 million in proceeds from maturities of marketable securities. Financing activities provided $40.5 million in cash, primarily from $42.8 million in proceeds from offering of common stock. At December 31, 2025, the company had $186.5 million in total assets, including $146.6 million in cash and cash equivalents. Total liabilities were $159.2 million, resulting in stockholders' equity of $27.3 million. The balance sheet shows $163.9 million in total current assets against $46.2 million in total current liabilities.
No specific management guidance, strategic priorities, or forward-looking statements were provided in the available financial data. The filing presents historical financial results without commentary on future expectations, growth projections, or strategic initiatives. Investors should refer to the complete 10-K filing for comprehensive risk factors and management discussion that typically accompany SEC filings, which were not included in the provided data extract.